Tokyo Tape
Sign in
← Vital Ksk Holdings

Quarterly report · Q1

3151.TEDINET S100RLIV
Period2023-04-01 → 2023-06-30
Filed2023-08-09
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥144.5bn2023-04-01 → 2023-06-30Cons.Net sales
Revenue¥581.3bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥143.9bn2022-04-01 → 2022-06-30Cons.Net sales
Operating income¥1.2bn2023-04-01 → 2023-06-30Cons.Operating income
Operating income¥849m2022-04-01 → 2022-06-30Cons.Operating income
Ordinary income¥1.5bn2023-04-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥6.0bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.2bn2022-04-01 → 2022-06-30Cons.Ordinary income
Profit before tax¥1.4bn2023-04-01 → 2023-06-30Cons.Income before income taxes
Profit before tax¥1.1bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)¥917m2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.8bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥640m2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income¥945m2023-04-01 → 2023-06-30Cons.Profit loss
Net income¥675m2022-04-01 → 2022-06-30Cons.Profit loss
Total assets¥305.7bnat 2023-06-30Cons.Assets
Total assets¥297.3bnat 2023-03-31Cons.Assets
Total assets¥314.2bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥203.5bnat 2023-06-30Cons.Liabilities
Total liabilities¥197.2bnat 2023-03-31Cons.Liabilities
Net assets / equity¥102.2bnat 2023-06-30Cons.Net assets
Net assets / equity¥100.2bnat 2023-03-31Cons.Net assets
Net assets / equity¥101.4bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥21.4bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥19.0bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥17.812023-04-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥92.692022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥12.052022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio33.0%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio33.3%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio31.9%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-06-30¥1.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-06-30¥1.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-06-30¥648m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-06-30−¥90m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥3.4bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥3.4bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30¥15m
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue2023-04-01 → 2023-06-30¥138.7bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue external2023-04-01 → 2023-06-30¥135.9bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥2.8bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentsegment profit2023-04-01 → 2023-06-30¥1.1bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥4.7bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥4.7bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥3m
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥87m
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥2.8bn
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥2.8bn
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥0
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥99m
—segment totalrevenue2023-04-01 → 2023-06-30¥146.1bn
—segment totalrevenue external2023-04-01 → 2023-06-30¥143.4bn
—segment totalrevenue intersegment2023-04-01 → 2023-06-30¥2.8bn
—segment totalsegment profit2023-04-01 → 2023-06-30¥1.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-06-30¥148.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-06-30¥144.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-06-30¥3.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-06-30¥1.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-06-30¥1.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-06-30¥1.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-06-30¥626m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-06-30−¥69m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥3.4bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥3.4bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30¥0
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue2022-04-01 → 2022-06-30¥138.4bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue external2022-04-01 → 2022-06-30¥135.6bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥2.8bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentsegment profit2022-04-01 → 2022-06-30¥783m
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥4.5bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥4.5bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥0
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥14m
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥2.7bn
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.7bn
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥0
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥121m
—segment totalrevenue2022-04-01 → 2022-06-30¥145.5bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥142.7bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥2.8bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥919m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥147.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥143.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥3.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥850m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 362
ItemContextValueUnit
Income taxes payablePrior1YearInstant2095000000JPY
Income taxes payableCurrentQuarterInstant615000000JPY
Provision for bonusesPrior1YearInstant1569000000JPY
Provision for bonusesCurrentQuarterInstant2417000000JPY
Other clPrior1YearInstant8462000000JPY
Other clCurrentQuarterInstant9464000000JPY
Current liabilitiesPrior1YearInstant178659000000JPY
Current liabilitiesCurrentQuarterInstant184129000000JPY
Long term loans payablePrior1YearInstant6790000000JPY
Long term loans payableCurrentQuarterInstant6547000000JPY
Other provision nclPrior1YearInstant251000000JPY
Other provision nclCurrentQuarterInstant252000000JPY
Net defined benefit liabilityPrior1YearInstant855000000JPY
Net defined benefit liabilityCurrentQuarterInstant774000000JPY
Other nclPrior1YearInstant10594000000JPY
Other nclCurrentQuarterInstant11810000000JPY
Noncurrent liabilitiesPrior1YearInstant18491000000JPY
Noncurrent liabilitiesCurrentQuarterInstant19384000000JPY
LiabilitiesPrior1YearInstant197150000000JPY
LiabilitiesCurrentQuarterInstant203513000000JPY
Capital stockPrior1YearInstant5000000000JPY
Capital stockCurrentQuarterInstant5000000000JPY
Capital surplusPrior1YearInstant12810000000JPY
Capital surplusCurrentQuarterInstant5272000000JPY
Retained earningsPrior1YearInstant67864000000JPY
Retained earningsCurrentQuarterInstant67380000000JPY
Treasury stockPrior1YearInstant-7575000000JPY
Treasury stockCurrentQuarterInstant-599000000JPY
Shareholders equityPrior1YearInstant78099000000JPY
Shareholders equityCurrentQuarterInstant77054000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant19972000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant23119000000JPY
Remeasurements of defined benefit plansPrior1YearInstant913000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant822000000JPY
Valuation and translation adjustmentsPrior1YearInstant20886000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant23942000000JPY
Non controlling interestsPrior1YearInstant1179000000JPY
Non controlling interestsCurrentQuarterInstant1203000000JPY
Net assetsPrior1YearInstant100165000000JPY
Net assetsCurrentQuarterInstant102199000000JPY
Liabilities and net assetsPrior1YearInstant297316000000JPY
Liabilities and net assetsCurrentQuarterInstant305713000000JPY
Net salesPrior1YTDDuration143919000000JPY
Net salesCurrentYTDDuration144542000000JPY
Cost of salesPrior1YTDDuration132786000000JPY
Cost of salesCurrentYTDDuration133079000000JPY
Gross profitPrior1YTDDuration11132000000JPY
Gross profitCurrentYTDDuration11462000000JPY
Selling general and administrative expensesPrior1YTDDuration10282000000JPY
Selling general and administrative expensesCurrentYTDDuration10295000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass